BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

ASRT: Convertible Offering Pauses Momentum

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul>
<li>Reporting better than expected Q2 results was not enough to keep investors interested after the earnings release </li>
<li>ASRT is in the process of broadening its sales channel for its recently acquired drug, Otrexup. ASRT should begin to generate a return on the drug in 2H2022</li>
<li>Indocin volume rose by approximately 7 percent sequentially. ASRT had increased prices in the second half of last year with investors concerned ASRT could face pushback from hospitals on pricing</li>
</ul>


Reporting better than expected Q2 results was not enough to keep investors interested after the earnings release 
ASRT is in the process of broadening its sales channel for its recently acquired drug, Otrexup. ASRT should begin to generate a return on the drug in 2H2022
Indocin volume rose by approximately 7 percent sequentially. ASRT had increased prices in the second half of last year with investors concerned ASRT could face pushback from hospitals on pricing


Assertio Holdings

ASRT: Low Valuation Growth